

INTERNATIONAL SEARCH REPORT

CITE NO. MM

International Application No  
PCT/US 02/12064

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07D213/75 C07D217/22 C07D401/12 C07D215/38 C07D403/12  
A61K31/44 A61K31/47 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MUIJLWIJK-KOEZEN, J.E. ET. AL.: "Isoquinoline and Quinazoline Urea Analogues as Antagonists for the Human Adenosine A3 Receptor." JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 11, 2000, pages 2227-38, XP002147879 Table 1, compounds 8a, 8b, 8d --- -/--	20, 21, 25, 28, 29, 32, 33

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

13 September 2002

Date of mailing of the international search report

20/09/2002

Name and mailing address of the ISA

Authorized officer

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/12064

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CARLING, R.W. ET. AL.: "1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl 1,3-dihydroimidazol-2-one: A Selective High Affinity Antagonist for the Human Dopamine D4 Receptor with Excellent Selectivity over Ion Channels" JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 14, 1999, pages 2706-15, XP001093697 Table 2, compound 7	20,21,28
X	US 4 279 639 A (OKAMOTO ET. AL.) 21 July 1981 (1981-07-21) examples 5-8	20,22
X	WO 99 32463 A (BAYER CORPORATION) 1 July 1999 (1999-07-01)  page 4, line 28 -page 7, line 17; claims	1,2,6,7, 9,11-15, 28,29,32
Y		1-39
X	WO 00 41698 A (BAYER CORPORATION) 20 July 2000 (2000-07-20)  Table 3, compound no. 9 page 6, line 29 -page 8, line 9	1,2,6,7, 11-15, 28,29,32
Y		1-39
A	DUMAS, J. ET. AL.: "1-Phenyl-5-pyrazolyl Ureas: Potent and Selective p38 Kinase Inhibitors." BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 10, 2000, pages 2051-4, XP004208309 tables 1-3	1-39
A	WO 99 32111 A (BAYER CORPORATION) 1 July 1999 (1999-07-01) page 5, line 15 -page 6, line 9; claims; examples	1-39
P,Y	WO 01 36403 A (BOEHRINGER INGELHEIM PHARMACEUTICALS INC.) 25 May 2001 (2001-05-25) claims; examples	1-39